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Abstract
Background:  ENSANUT  2012  showed  a  combined  prevalence  of  overweight  and  obesity  of  34.4%
in Mexican  children.  Single  nucleotide  polymorphisms  (SNPs)  of  the  ADIPOQ  and  ADIPOR2  genes
have been  reported  in  many  populations,  but  their  association  with  obesity  has  not  been  con-
ﬁrmed in  other  studies.  Our  aim  was  to  determine  the  association  of  SNPs  from  ADIPOQ  and
ADIPOR2 genes  with  obesity  in  Mexican  children.
Methods:  A  total  of  2,634  children  from  6  to  12  years  old  were  enrolled  in  the  study  from  four
IMSS Units  in  Mexico  City.  We  selected  1,469  unrelated  children  (745  normal  weight  and  724
overweight/obese).  Phenotype  characterization  included  anthropometric  measurements,  blood
pressure,  biochemical  parameters,  insulin  concentrations  and  presence  of  acanthosis  nigricans
(AN). Analysis  of  the  SNPs  rs182052,  rs266729,  rs2241766,  rs822393  of  ADIPOQ  and  rs11061971
of ADIPOR2  was  carried  out  in  the  DNA  samples.
Results:  The  study  showed  signiﬁcant  differences  (p  <0.05)  between  groups  in  waist  circum-
ference, blood  pressure,  presence  of  AN,  insulin  concentrations,  HOMA-IR,  fasting  glucose  and
lipid parameters,  being  higher  in  obese  children.  No  associations  in  ADIPOQ  variants  with  the
presence  of  overweight/obesity  were  found.  The  presence  of  the  variant  rs11061971  of  ADIPOR2
in children  had  a  signiﬁcant  association  with  protection  of  overweight/obesity  (OR  0.79,  95%
so,  the  log-additive  model  conﬁrmed  the  association  by  codominant
.05).CI 0.68-0.93,  p  =  0.003).  Al
and dominant  models  (p  <0∗ Corresponding author.
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Conclusions:  The  presence  of  rs11061971  of  ADIPOR2  variant  confers  protection  against  obesity
and could  be  used  as  a  marker  in  Mexican  children.
© 2014  Hospital  Infantil  de  México  Federico  Gómez.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
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Polimorﬁsmos  de  los  genes  ADIPOQ  y  ADIPOR2  y  su  asociación  con  sobrepeso/
obesidad  en  nin˜os  mexicanos
Resumen
Introducción:  ENSANUT  2012  mostró  una  prevalencia  combinada  de  sobrepeso  y  obesidad  en
el 34.4%  en  nin˜os  mexicanos.  Se  han  reportado  polimorﬁsmos  de  un  solo  nucleótido  (SNP)  de
los genes  ADIPOQ  y  ADIPOR2  en  varias  poblaciones,  pero  su  asociación  con  la  obesidad  ha  sido
controversial.  El  objetivo  de  este  trabajo  fue  determinar  la  asociación  de  SNP  de  ADIPOQ  y
ADIPOR2 con  obesidad  en  una  muestra  de  nin˜os  mexicanos.
Métodos:  Un  total  de  2,634  nin˜os  de  6-12  an˜os  se  inscribieron  en  el  estudio  en  cuatro  unidades
del Instituto  Mexicano  del  Seguro  Social  en  la  Ciudad  de  México.  Se  seleccionaron  1,469
nin˜os no  emparentados  (745  peso  normal  y  724  sobrepeso/obesidad).  Se  les  tomaron  medidas
antropométricas,  presión  arterial,  parámetros  bioquímicos,  insulina  y  presencia  de  acantosis
nigricans (AN).  El  análisis  de  los  SNP  (rs182052,  rs266729,  rs2241766,  rs822393  de  ADIPOQ  y
rs11061971  de  ADIPOR2) se  realizó  en  muestras  de  ADN.
Resultados:  Se  observaron  diferencias  signiﬁcativas  (p  <  0.05)  entre  los  grupos  en  la  circun-
ferencia de  cintura,  presión  arterial,  AN,  insulina,  HOMA-IR,  glucosa  en  ayunas  y  parámetros
lipídicos siendo  elevados  en  los  nin˜os  obesos.  No  se  encontró  asociación  en  variantes  ADIPOQ
con la  presencia  de  sobrepeso/obesidad.  La  presencia  de  rs11061971  de  ADIPOR2  tuvo  una  aso-
ciación signiﬁcativa  con  la  protección  de  sobrepeso/obesidad  (OR  de  0.79;  IC95%  0.68  a  0.93,
p =  0.003).  El  modelo  Log-aditivo  conﬁrmó  la  asociación  de  los  modelos  codominante  y  domi-
nante (p  <  0.05).
Conclusiones:  La  presencia  de  la  variante  rs11061971  de  ADIPOR2  conﬁere  protección  contra
la obesidad,  y  podría  utilizarse  como  marcador  en  nin˜os  mexicanos.
© 2014  Hospital  Infantil  de  México  Federico  Gómez.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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c1. Introduction
Obesity  is  a  public  health  problem  that  has  increased
dramatically  in  recent  years,  with  epidemic  proportions
worldwide.1--4 Obesity  in  Mexico  is  increased  on  average
of  1.1  percentage  points  per  year.  The  ENSANUT  2012
showed  a  combined  prevalence  of  overweight  and  obesity
of  34.4%  in  both  sexes  in  children.  It  represents  about
5,664,870  overweight  and  obese  children  in  a  national
population.5
Many  factors  are  associated  with  obesity  in  childhood,  for
example,  lack  of  physical  activity,  diets  with  high  content
of  carbohydrates  and  the  genetic  predisposition.6,7 Pre-
vious  studies  have  concluded  that  high  concentration  of
adiponectin  predict  a  lower  prevalence  of  type  2  diabetes
(T2D)  in  Mexican  children8 and  that  serum  adiponectin  can
be  a  biomarker  to  predict  metabolic  syndrome  in  eutrophic
and  obese  children.9Adiponectin  binds  to  its  receptors  (AdipoR1  and  Adi-
poR2)  for  signaling  actions.  Adiponectin  exhorts  its  effects
through  the  sensitization  of  the  body  to  the  insulin10,11
c
r
Py  activating  numerous  signaling  molecules  including
denosine  monophosphate-activated  protein  kinase  (AMPK),
38-MAPK,  JNK,  PPAR transcription  factor  and  NF-B  in
ultiple  tissues.  These  signals  are  transduced  via  the
dipoRs.12,13 Mechanisms  regulating  the  expression  of  Adi-
oRs  appear  to  be  complex  and  are  governed  by  numerous
actors.
The  polygenic  nature  of  obesity  and  the  interactions
f  single  nucleotide  polymorphisms  (SNPs)  in  over-
eight/obesity  are  not  clear.14 SNPs  of  the  ADIPOQ  gene
ave  been  reported  in  many  populations;  however,  some
f  these  associations  with  obesity  could  not  be  con-
rmed  in  other  studies.  The  human  ADIPOR2  gene  is
enerally  not  associated  with  serum  adiponectin  but  is
ssociated  with  insulin  resistance  and  T2D  risk  in  genetic
ssociation  studies,  but  the  mechanisms  are  not  yet
lear.15--19
The  aim  of  present  study  was  to  determine  the  asso-
iation  of  obesity  with  SNP  variants  rs182052,  rs266729,
s2241766,  rs822393  of  ADIPOQ  and  the  rs11061971  of  ADI-
OR2  genes  in  Mexican  children.
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. Methods
.1.  Participants
 total  of  2,634  children  from  6--12  years  old  were  enrolled
n  the  study  from  four  IMSS  Units  in  Mexico  City:  Cuauhté-
oc,  Nezahualcóyotl,  Independence  and  Morelos  (north,
ast,  south,  and  northeast  corresponding  areas).  A  general
escription  of  the  children  studied  is  shown  in  Table  1.
hildren  were  randomly  selected  to  participate  in  a  cross-
ectional  study  between  July  2011  and  July  2012.
Unrelated  children  (n  =  1,469)  were  classiﬁed  into  nor-
al  weight  (n  =  745)  and  overweight/obesity  (n  =  724)
roups  according  to  their  body  mass  index  (BMI)  percentile
escribed  by  the  U.S.  Centers  for  Disease  Control  and  Pre-
ention  (CDC).  Children  with  autoimmune  diseases,  cancer
r  other  diseases  related  to  obesity  were  excluded.  The
tudy  was  conducted  after  informed  consent  was  signed  by
arents  and  children,  respectively.  The  National  Commit-
ee  and  the  Ethics  Committee  Board  from  the  IMSS  National
esearch  Commission  approved  the  protocol.
.2.  Procedure
nvitation  for  the  study  was  conducted  in  each  unit  men-
ioned.  The  personnel  enrolled  in  the  project  explained
he  beneﬁts  of  participation  in  the  study.  Participants  were
valuated  with  questionnaires  and  anthropometric  measure-
ents,  and  biochemical  and  genetic  studies  were  applied.
ach  of  the  steps  was  performed  according  to  related  norms
nd  clinical  guidelines.
.3.  Clinical  records
ll  participants  were  weighed  using  a  digital  scale  (Seca,
amburg,  Germany).  Height  was  measured  with  a  portable
tadiometer  (Seca  225)  and  waist  circumference  (WC)  was
easured  at  the  midpoint  between  the  lowest  rib  and  the
liac  crest  after  a  normal  exhalation  with  children  in
he  standing  position.  Body  mass  index  (BMI)  was  calculated
nd  classiﬁed  according  to  the  CDC  2000  (Atlanta,  GA,  USA)
eferences  (eutrophic  children  10th  to  <85th  percentile,
verweight  children  ≥85th  to  <95th  percentile  and  obese
hildren  ≥95th  percentile  in  BMI).  Blood  pressure  was  mea-
ured  by  auscultatory  method  using  a  mercurial  sphygmo-
anometer  (ALPK2,  Tokyo,  Japan)  with  appropriate  cuff  size
or  arm  length  following  North  American  guidelines  issued
n  2004.  Blood  pressure  readings  were  taken  for  each  par-
icipant  twice,  on  the  right  arm  in  a  sitting  position,  resting
 min  between  each  measurement,  and  considering  the  level
f  blood  pressure  as  the  mean  of  the  readings.  The  pres-
nce  of  acanthosis  nigricans  (AN)  was  recorded  in  the  neck,
rmpit,  under  the  breast  or  a  skin  crease  and  is  described
s  positive  if  presented  in  any  of  the  areas  mentioned.
.4.  Biochemical  studieslood  samples  were  taken  in  children  after  a  12-h  fast.
iochemical  analysis  included  fasting  glucose,  total  choles-
erol,  HDL-C  and  LDL-C  and  triglycerides  using  the  ILab  350
w
s
w
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linical  Chemistry  System  (Instrumentation  Laboratory  IL,
arcelona,  Spain).  Insulin  (U/mL)  was  measured  by  chemi-
uminiscence  (IMMULITE)  and  the  HOMA-IR  was  calculated
or  insulin  resistance.
.5.  Genotyping  and  genetic  analysis
enomic  DNA  was  isolated  from  peripheral  blood  using  a
tandard  protocol  for  DNA  extraction  with  a  FLEX  STAR  Auto-
en  (Holliston,  MA).  All  samples  were  run  in  0.8%  agarose
els  stained  with  ethidium  bromide  to  verify  the  integrity
nd  purity  by  260/280  DO.  We  selected  the  most  promising
NPs  of  the  adiponectin  gene  and  the  receptor  and  minor
llele  frequencies  ≥10%  in  the  Mexican  population  accord-
ng  to  the  HapMap  database.  SNPs  were  rs182052,  rs266729,
s2241766,  and  rs822393  of  ADIPOQ  and  rs11061971  of
DIPOR2.  Genotyping  was  performed  using  the  TaqMan  Ope-
Array  Real-Time  PCR  System  (Life  Technologies,  Carlsbad,
A)  following  the  manufacturer’s  instructions.  The  geno-
ype  success  rate  was  at  least  98%,  and  no  deviation
p  ≥0.05)  from  Hardy-Weinberg  equilibrium  was  observed  in
he  analysis.  Thirty  random  samples  were  done  in  duplicate
or  genotype  quality  control  with  100%  concordance.
.6.  Statistical  analysis
ests  were  performed  to  check  whether  there  were  sig-
iﬁcant  differences  between  cases  and  controls  for  the
nthropometric  and  biochemical  variables.  Comparison
etween  groups  was  done  using  the  t  test  for  continuous
ariables.  For  categorical  data  we  used  2 test.  Logistic
egression  models  were  performed  to  evaluate  the  asso-
iation  of  overweight/obesity  in  different  genotypes.  We
btained  odds  ratios  (OR)  with  95%  conﬁdence  intervals  (CI)
n  the  three  main  inheritance  models:  codominant,  dom-
nant  and  recessive,  adjusted  by  age,  gender  and  WHR.
tatistical  analysis  was  performed  using  STATA  11  software
Stata  Corp  LP,  College  Station,  TX).  We  used  the  Stata  pro-
ram  to  estimate  the  statistical  signiﬁcance  of  p  <0.05  and
5%  CI  in  the  study  for  each  SNP  with  an  expected  OR  of
.2,  1.5,  2,  2.5;  alpha  =  0.05  and  the  minor  allele  frequency
MAF)  for  each  SNP  and  each  population  in  the  study.
. Results
able  1  shows  the  general  characteristics  of  the  2634  chil-
ren  studied.  The  presence  of  obesity  ranged  from  22-32%
n  the  four  units.  Overweight  and  obesity  was  higher  in
uauhtémoc  Unit,  23.27%  and  32.50%,  respectively,  whereas
he  Independencia  Unit  showed  the  lowest  percentage.
Table  2  shows  the  characteristics  of  the  unrelated  chil-
ren  (n  =  1,469).  The  analysis  comparison  of  normal  weight
hildren  vs.  overweight/obesity  according  to  gender  was
imilar  in  both  groups.  Family  history  of  obesity  was  sim-
lar  in  children  with  normal  weight  and  overweight/obese
roups.  The  presence  of  AN  was  higher  in  the  over-
eight/obesity  group  (p  <0.0001).  Waist  circumference  was
igniﬁcant  (p  <0.001)  when  comparing  the  groups  and
as  14  cm  higher  in  children  with  overweight/obesity.
ystolic  and  diastolic  blood  pressures  were  signiﬁcant
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Table  1  General  characteristics  of  the  four  units  from  the  IMSS  (n  =  2634).
BMI  IMSS  unit  Total
Cuauhtémoc  Nezahualcóyotl  Independencia  Morelos
Underweight  6  (1.07%)  11  (2.06%)  15  (2.27%)  20  (2.28%)  52  (1.97%)
Normal weight  243  (43.16%)  277  (51.87%)  375  (56.82%)  477  (54.39%)  1372  (52.09%)
Overweight  131  (23.27%)  119  (22.28%)  124  (18.79%)  167  (19.04%)  541  (20.54%)
Obesity 183  (32.50%)  127  (23.78%)  146  (22.12%)  213  (24.29%)  669  (25.40%)
Total 563  534  660  877  2634  (100%)
ed.
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4Data represented in frequency and percentages by IMSS unit studi
in  children  with  overweight/obesity  (p  <0.001).  Bio-
chemical  parameters  showed  statistical  signiﬁcance  in
fasting  glucose  and  insulin  measured  by  HOMA-IR  in  over-
weight/obese  children.  Lipids  were  elevated  in  children
with  overweight/obesity  compared  to  normal  weight  chil-
dren.  Triglyceride  concentration  increased  to  30  mg/dL  in
children  with  overweight  and  obesity.
Table  3  shows  the  allele  frequencies  and  genotypes
rs182052,  rs266729,  rs2241766,  rs822393  of  ADIPOQ  and
rs11061971  of  ADIPOR2  SNPs  being  displayed  according  to
BMI  children.  All  polymorphisms  studied  were  in  Hardy-
Weinberg  equilibrium  (HWE).
Table  4  shows  the  effect  of  the  ﬁve  polymorphisms  and
the  risk  of  overweight/obesity  with  ORs  estimated  through
A
i
S
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Table  2  Clinical  characteristics  of  unrelated  children  studied  (n  
Normal  weight  
n  =  745  
Gender  (%)
Female  50.76  
Male 49.24  
Family history  of  obesity  (%)
Yes 42.72
No 58.51
Presence  of  acanthosis  nigricans  (%)
Yes 19.1  
No 80.9  
Age (years)  9.12  ±  2.11  
BMI (kg/m2)  16.73  ±  2.11  
WC (cm)  58.96  ±  7.04  
DBP (mmHg)  64.47  ±  8.41  
SBP (mmHg)  95.89  ±  10.35  
FG (mg/dl)  81.96  ±  9.67  
Insulin (IU/ml)  5.22  ±  4.12  
HOMA-IR 1.03  ±  0.89  
TC (mg/dl)  154.16  ±  31.93  
TG (mg/dl)  76.65  ±  31.45  
HDL (mg/dl)  53.85  ±  12.35  
LDL (mg/dl)  98.07  ±  23.84  
Results are shown as percentages for categorical variables and mean ±
BMI, body mass index; WC, waist circumference; DBP, diastolic blood pre
Homeostasis Model Assessment-Insulin Resistance; TC, total cholesterol;
lipoprotein.
* p values correspond to the t-test for age, Mann-Whitney U test for ogistic  regression  adjusted  by  age,  gender  and  family  his-
ory  of  obesity.  No  association  with  obesity  was  shown  in
DIPOQ  SNPs,  whereas  the  ADIPOR2  rs11061971  polymor-
hism  had  a  signiﬁcant  protective  effect  (OR  0.79,  95%  CI
.68-0.93,  p  =  0.003)  in  the  log-additive  model.  This  asso-
iation  was  conﬁrmed  by  codominant  and  dominant  model
p  <0.05).
.  Discussiondiponectin  plays  a  role  in  obesity  displaying  anti-
nﬂammatory  and  anti-atherogenic  actions.20--22 Several
NPs  were  reported  associated  in  obese  children;  however,
nly  few  studies  in  Mexican  children  have  been  reported.  We
=  1469).
Overweight/obesity  p  value*
n  =  724
50.43
49.57  0.89
41.49  <0.0001
57.28
63.7  <0.0001
36.3
9.38  ±  2.03  <0.01
22.69  ±  3.66  <0.001
74.36  ±  10.63  <0.001
67.62  ±  8.41  <0.001
101.12  ±  11.04  <0.001
82.64  ±  9.35  <0.003
10.18  ±  9.35  <0.001
2.09  ±  2.10  <0.001
162.18  ±  75.67  <0.006
111.23±57.99  <0.001
47.08±12.37  <0.001
106.85±28.12  <0.001
 standard deviation for continuous variables.
ssure; SBP, systolic blood pressure; FG, fasting glucose; HOMA-IR,
 TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density
continuous variables and 2 for categorical variables.
30  J.J.  Peralta  Romero  et  al.
Table  3  Genotypic,  allelic  frequencies  and  HWE  of  ADIPOQ  and  ADIPOR2  genes.
Gen  SNP  BMI  Genotypes  Allele  frequencies  HWE  (p  value)
ADIPOQ  rs182052  AA  AG  GG  A  G
All  subjects  413  (29)  708  (49)  315  (22)  1534  (53)  1338  (47)  0.75
Nwa 208  (29)  347  (47)  173  (24)  763  (52)  693  (48)  0.23
Ow/Obb 205  (29)  361  (51)  142  (20)  771  (54)  645  (46)  0.5
rs266729 CC  CG  GG  C  G
All subjects 542  (38) 693  (48) 209  (14)  1777  (62)  1111  (38)  0.62
Nw a 289  (40) 347  (47) 97  (13) 925  (63) 541  (37) 0.69
Ow/Ob b 253  (36) 346  (49) 112  (15) 852  (60) 570  (40) 0.76
rs2241766  TT  TG  GG  T  G
All subjects  940  (67)  431(30)  47  (3)  2311  (81)  525  (19)  0.86
Nw a 476  (67) 214  (30)  27  (3)  1166  (81)  268  (19)  0.62
Ow/Ob b 464  (67) 217  (30) 20  (3)  1145  (82)  257  (18)  0.45
rs822393 CC  CT  TT  C  T
All subjects 414  (29) 699  (49) 329  (22) 1527  (53)  1357  (47)  0.32
Nw 225  (30)  349  (48)  161  (22)  799  (54)  671  (46)  0.26
Ow/Ob 189  (27)  350  (50)  168  (23)  728  (51)  686  (49)  0.82
ADIPOR2 rs11061971  TT  TA  AA  T  A
All  subjects  589  (41)  661  (46)  186  (13)  1839  (64)  1033  (36)  1
Nw 275  (38)  350  (48)  104  (14)  900  (62)  558  (38)  0.7
Ow/Ob 314  (44) 311  (44)  82  (12)  939  (66)  475  (34)  0.74
The results are shown as numbers of patients for each genotype and allele frequency. Data in parentheses are given in percentages.
HWE, Hardy-Weinberg equilibrium; BMI, body mass index; Nw, normal weight; Ow,Ob, overweight/obesity.
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Pnvestigated  the  distribution  of  ADIPOQ  and  ADIPOR2  poly-
orphisms  in  children  from  Mexico  City.  Our  study  showed
o  association  between  ADIPOQ  gene  variants  in  obesity.
nly  ADIPOR2,  rs11061971  showed  a  protective  association
gainst  obesity  (Table  4).
Several  reports  showed  an  association  of  ADIPOQ  gene
ariants  with  obesity  or  its  comorbidities  such  as  MetS.
owever,  these  results  have  not  been  convincing  in  repli-
ation  studies  in  other  populations;  therefore,  it  seems  to
e  playing  an  important  role  in  the  ancestry  of  the  popula-
ions  studied.  Our  study  includes  four  different  geographical
egions  of  Mexico  City  where  we  observed  differences  in  BMI
revalence.
Signiﬁcant  associations  between  obesity  and  polymor-
hisms  in  the  gene  coding  for  ADIPOQ  have  been  reported
n  other  studies. 23,24 Guzman-Ornelas  et  al.  suggested  that
olymorphisms  in  the  gene  coding  for  ADIPOQ  could  be
ssociated  with  distribution  of  body  fat  storage  in  adult
besity.  On  the  other  hand,  no  association  was  observed
etween  gene  polymorphisms  and  obesity  in  a  Mexican-
estizo  population.25
The  rs2241766  polymorphism  of  ADIPOQ  has  not  been
ssociated  with  obesity  but  has  had  signiﬁcant  associa-
ions  in  comorbidities  such  as  MetS.26 However,  few  studies
ave  investigated  the  relationship  between  rs266729  poly-
orphism  and  risk  of  obesity  or  MetS.  Regarding  links
etween  rs266729  and  MetS,  early  studies  reported  varying
esults.27,28 The  rs182052  was  associated  with  an  increased
p
d
gisk  of  the  prevalence  of  obesity  in  adult  Korean  women,
ut  there  were  no  signiﬁcant  interactions  observed  between
he  genotype  of  ADIPOQ  rs182052  and  dietary  intake  on
MI  and  body  fat  mass.  These  ﬁndings  suggest  that  the
besity-related  variables  may  be  more  dominantly  affected
y  the  genotype  of  ADIPOQ  rs182052  than  dietary  intake
n  middle-aged  Korean  women.  MAF  in  a  Korean  popula-
ion  (0.49)  was  different  from  European  (0.40),  Chinese
0.42)  and  Mexican  (0.22)  populations.29 No  study  has
eported  the  relationship  between  rs822393  of  ADIPOQ
nd  obesity.  Ramya  et  al.  in  2013  described  that  there
as  no  association  with  T2D  but  there  was  an  association
ith  decreased  adiponectin  values.30 On  the  other  hand,
he  rs822393  of  ADIPOQ  was  not  associated  in  Mexican
hildren.
The  role  of  ADIPOR2  in  obesity  could  arise  from
he  unique  function  of  this  receptor  in  mediating  the
ffects  of  adiponectin  in  the  liver.  Adiponectin  inﬂu-
nces  fat  metabolism,  increasing  fatty  acid  oxidation
hrough  activation  of  AMP-activated  protein  kinase  which,
n  turn,  phosphorylates  acetyl  CoA  carboxylase.10 Lui  et  al.
emonstrated  a  role  of  ADIPOR2  in  the  pathogenesis  of
nsulin  resistance  (IR)  syndrome  and  T2D  and  suggest  ADI-
OR2  as  a promising  target  for  the  treatment  of  T2D
atients,  particularly  those  who  have  adiposity,  IR  and
yslipidemia.18
There  are  few  studies  of  variant  rs11061971  of  ADIPOR2
ene.  No  data  exist  in  the  National  Center  for  Biotechnology
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Table  4  Estimated  effect  of  association  by  Mendelian  inheritance  model  of  ADIPOQ  and  ADIPOR2  polymorphism  with
overweight/obesity.
Genes  SNP  Model  OR  95%  CI  p  value  P  trend
ADIPOQ rs2241766
T/Tc 1
T/Gc 1.05  0.83-1.32  0.74
G/Gc 0.77  0.42-1.40  0.39
T/G +  G/Gd 1.02  0.81-1.27  0.89  0.82
G/Gr 0.76  0.42-1.37  0.36
Log-additive  0.98  0.81-1.19  0.86
rs822393
C/Cc 1
C/Tc 1.21  0.94-1.55  0.1
T/Tc 1.23  0.91-1.65  0.15
C/T +  T/Td 1.21  0.96-1.53  0.1  0.13
T/Tr 1.09  0.85-1.40  0.49
Log-additive  1.11  0.96-1.29  0.15
rs182052
G/Gc 1
G/Ac 1.06  0.83-1.36  0.59
A/Ac 0.83  0.62-1.12  0.2  0.26
G/A +  A/Ad 0.99  0.78-1.24  0.91
A/Ar 0.8  0.62-1.03  0.08
Log-additive  0.92  0.79-1.07  0.28
rs266729
C/Cc 1
C/Gc 1.18  0.94-1.48  0.13
G/Gc 1.31  0.95-1.81  0.11  0.07
C/G +  G/Gd 1.21  0.97-1.50  0.09
G/Gr 1.19  0.89-1.61  0.24
Log-additive  1.15  0.99-1.34  0.07
ADIPOR2 rs11061971
T/Tc 1
T/Ac 0.74  0.59-0.93  0.01
A/Ac 0.67  0.48-0.93  0.01  0.004
T/A +  A/Ad 0.72  0.58-0.90  0.003
A/Ar 0.78  0.57-1.07  0.12
Log-additive  0.79  0.68-0.93  0.003
Results are described according to the models: ccodominant, ddominant, rrecessive and log-additive; adjusted by age, gender and family
history of obesity.
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cSNP, single nucleotide polymorphisms; OR, odds ratio; CI, conﬁden
Information  (NCBI)  for  the  Mexican  or  Latino  population.
Studies  in  the  Russian  population  showed  that  ADIPOR2,
rs11061971  has  an  association  with  T2D.19 Similarly,  Damcott
et  al.  reported  that  the  T  allele  of  rs11061971  was  signiﬁ-
cantly  associated  with  a  higher  risk  of  T2D.31 The  alleles
of  ADIPOR2  forming  the  common  haplotype  AG  were  associ-
ated  with  a  reduced  risk  of  T2D.  The  protective  role  of  this
haplotype  in  the  development  of  T2D  could  be  attributed  to
its  association  with  a  decreased  HOMA-IR  value  and,  there-
fore,  with  reduced  IR.  In  addition,  the  AG  haplotype  showed
an  association  with  lower  serum  concentrations  of  trigly-
cerides.  Other  studies  also  found  the  relationship  between
multiple  ADIPOR2  variants  and  triglyceride  levels  but  not
with  obesity.32,33 ADIPOR2  variant  was  observed  as  being
protective  for  obesity  in  Mexican  children.
C
T
nterval.
The  Mexican  population  is  at  relatively  high  risk  for  obe-
ity,  IR  and  T2D.  The  genetic  variation  in  candidate  genes
f  ADIPOQ  and  ADIPOR2  could  inﬂuence  variation  in  such
isease  conditions  and  related  traits.  In  the  present  study
e  provide  evidence  that  the  ADIPOR2  polymorphism  is
ssociated  with  protection  for  obesity  in  Mexican  children.
herefore,  the  presence  of  rs11061971  polymorphism  of  ADI-
OR2  could  be  used  as  a  protective  marker  for  obesity  in
hildren.onﬂict of interest
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